Clinical Trial Detail

NCT ID NCT03822351
Title Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedImmune LLC
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Durvalumab + Monalizumab

Durvalumab + Oleclumab

Age Groups: senior adult

No variant requirements are available.